KOPRAN vs ZIMLAB: Stock Comparison

Kopran Limited vs Zim Laboratories Limited

Live data: 29 May 2026, 4:01 PM IST • Source: NSE and company filings

Kopran Limited is the larger company by market capitalisation. Kopran Limited shows a lower P/E, a higher ROE and a higher dividend yield, while Zim Laboratories Limited shows faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Kopran Limited and Zim Laboratories Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, KOPRAN is more favourable on 11 of 13 scored metrics and ZIMLAB on 2These counts are context-free and are not an overall rating.

Key Differences

Market Cap
KOPRAN is the larger company
₹942 Cr vs ₹656 Cr
P/E Ratio
KOPRAN has a lower P/E
38.28x vs 112.39x
P/B Ratio
KOPRAN has a lower P/B
1.86x vs 2.21x
EPS
KOPRAN has higher earnings per share
₹3.41 vs ₹1.94
Dividend Yield
KOPRAN has a higher dividend yield
1.59% vs 0.02%
Revenue Growth (TTM YoY)
ZIMLAB has faster revenue growth
-3.36% vs -3.66%
EPS Growth (TTM YoY)
ZIMLAB has faster EPS growth
-47.01% vs -71.88%
Qtr Sales Growth
KOPRAN has stronger quarterly sales growth
-3.03% vs -12.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricKOPRANZIMLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricKOPRANZIMLAB
Live Price₹206.27₹104.91
Day Change6.56%0.25%
Volume38.55 L81,241
52-Week High₹219₹121.47
52-Week Low₹107₹59.31
Distance from 52W High-5.81%-13.63%

Valuation

MetricKOPRANZIMLAB
Market Cap₹942 Cr₹656 Cr
P/E Ratio38.28x112.39x
P/B Ratio1.86x2.21x
EPS₹3.41₹1.94
Book Value₹107.35₹51.77
Dividend Yield1.59%0.02%

Growth

MetricKOPRANZIMLAB
Revenue Growth (TTM YoY)-3.66%-3.36%
EPS Growth (TTM YoY)-71.88%-47.01%
Qtr Sales Growth-3.03%-12.3%
Qtr Profit Growth-32.9%-308%

Profitability & Leverage

MetricKOPRANZIMLAB
ROE4.85%1.97%
ROCE9.75%8.16%
Net Margin3.78%1.56%
Operating Margin6.58%5.72%
Debt to Equity0.29x0.42x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricKOPRANZIMLAB
Promoter Holding44.42%30.36% 0.01 pp
FII Holding0.51% 0.06 pp0.03% 0.03 pp
DII Holding0%1.33% 1.26 pp
Public Holding55.06% 0.06 pp68.28% 1.3 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Kopran Limited and Zim Laboratories Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.